The CCR5 sensitivity screens by Incelldx in human cancer cells (the link I provided) were conducted in 2018. CYDY started down the mTNBC path in late 2018, early 2019, far before COVID became a pandemic. My statement was in regards to CYDY starting a trial for urothelial cancer around the same time considering the results of the sensitivity screens. These patients can be included in the basket trial, but a trial devoted to the cancer with the highest concentration of CCR5 sensitivity would seem like a good decision (no funding for that now, but maybe in the near future).